Research programme: orphan disease therapeutics - Aevi Genomic Medicine/The Childrens Hospital of Philadelphia

Drug Profile

Research programme: orphan disease therapeutics - Aevi Genomic Medicine/The Childrens Hospital of Philadelphia

Alternative Names: MDGN-204; MDGN-206

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medgenics; The Childrens Hospital of Philadelphia
  • Developer Aevi Genomic Medicine; The Childrens Hospital of Philadelphia
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Metabolic disorders

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 06 Jan 2016 Medgenics in-licenses GeneRide promoter-less gene therapy technology from Stanford University
  • 12 Nov 2014 Medgenics and The Children's Hospital of Philadelphia enter into a collaboration collaboration to develop orphan disease therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top